StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Zevra Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $33.40M. For fiscal 2025 it was -$1.60M. The highest annual figure on record is $10.44M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.60M–
FY2024Dec 31, 2024-$69.67M–
FY2023Dec 31, 2023-$33.54M–
FY2022Dec 31, 2022-$18.72M-279.3%
FY2021Dec 31, 2021$10.44M–
FY2020Dec 31, 2020-$1.94M–
FY2019Dec 31, 2019-$23.74M–
FY2018Dec 31, 2018-$54.20M–
FY2017Dec 31, 2017-$33.10M–
FY2016Dec 31, 2016-$29.77M–
FY2015Dec 31, 2015-$20.27M–
FY2014Dec 31, 2014-$14.67M–
FY2013Dec 31, 2013-$4.33M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.03M–
Q1 FY2026Mar 31, 2026$6.14M–
Q4 FY2025Dec 31, 2025$5.52M–
Q3 FY2025Sep 30, 2025$4.71M–
Q2 FY2025Jun 30, 2025-$3.60M–
Q1 FY2025Mar 31, 2025-$8.22M–
Q4 FY2024Dec 31, 2024-$16.25M–
Q3 FY2024Sep 30, 2024-$18.14M–
Q2 FY2024Jun 30, 2024-$19.11M–
Q1 FY2024Mar 31, 2024-$16.17M–
Q4 FY2023Dec 31, 2023-$16.16M–
Q3 FY2023Sep 30, 2023-$4.63M–
Q2 FY2023Jun 30, 2023-$8.70M–
Q1 FY2023Mar 31, 2023-$4.05M–
Q4 FY2022Dec 31, 2022-$4.46M–
Q3 FY2022Sep 30, 2022-$6.60M–
Q2 FY2022Jun 30, 2022-$4.10M-124.7%
Q1 FY2022Mar 31, 2022-$3.55M–
Q4 FY2021Dec 31, 2021-$848.00K–
Q3 FY2021Sep 30, 2021-$2.73M–
Q2 FY2021Jun 30, 2021$16.60M+657.1%
Q1 FY2021Mar 31, 2021-$2.59M–
Q4 FY2020Dec 31, 2020-$1.06M–
Q3 FY2020Sep 30, 2020-$1.05M–
Q2 FY2020Jun 30, 2020$2.19M–
Q1 FY2020Mar 31, 2020-$2.02M–
Q4 FY2019Dec 31, 2019-$3.10M–
Q3 FY2019Sep 30, 2019-$2.23M–
Q2 FY2019Jun 30, 2019-$7.34M–
Q1 FY2019Mar 31, 2019-$11.07M–
Q4 FY2018Dec 31, 2018-$15.00M–
Q3 FY2018Sep 30, 2018-$15.95M–
Q2 FY2018Jun 30, 2018-$9.15M–
Q1 FY2018Mar 31, 2018-$14.10M–
Q4 FY2017Dec 31, 2017-$6.94M–
Q3 FY2017Sep 30, 2017-$10.17M–
Q2 FY2017Jun 30, 2017-$6.47M–
Q1 FY2017Mar 31, 2017-$9.52M–
Q4 FY2016Dec 31, 2016-$9.36M–
Q3 FY2016Sep 30, 2016-$8.27M–

More Zevra Therapeutics figures

See a number that looks wrong?